Claudin18.2 Recombinant Antibody: Enhance Your Research Today

As a researcher in the field of immunology, I often seek high-quality reagents for my experiments. The Claudin18.2 recombinant antibody stands out as a top choice in my toolkit. It's specifically designed for targeting Claudin18.2, making it ideal for applications like immunohistochemistry and Western blotting. I trust its specificity and sensitivity, allowing me to obtain reliable results, Choosing Alpha Lifetech Incorporation is a no-brainer for me. Their commitment to producing exceptional antibodies ensures I get consistent performance every time. Whether you're working on cancer research or other applications related to tight junctions, this antibody can provide valuable insights. The reliability and quality I’ve experienced with their products have made a significant difference in my work. If you’re aiming for precision in your research, I highly recommend considering this Claudin18.2 recombinant antibody from Alpha Lifetech

Hot Selling Product

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a Protein, His Tag

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

ALP64517-Recombinant Human CD223/LAG3 Protein, His Tag, Avi Tag

ALP64519-Recombinant Human CD3E/CD3 Epsilon Protein, mFc Tag

Trending Claudin18.2 recombinant antibody in 2025 Service Backed by Expertise

In 2025, the demand for Claudin18.2 recombinant antibodies is set to rise dramatically, driven by advancements in cancer research and therapeutic applications. At Alpha Lifetech Inc., we are at the forefront of this trend, leveraging our extensive expertise in membrane Protein production and monoclonal antibody development. Our dedicated team of scientists has meticulously engineered a robust portfolio of high-quality Claudin18.2 antibodies, facilitating groundbreaking work in targeted cancer therapies and diagnostic innovations. Our commitment to quality is evident in our continuous production of nearly 10,000 specialized reagents, including cytokines and drug target antibodies. By combining years of research and development with state-of-the-art technology, we ensure that our Claudin18.2 recombinant antibodies meet the highest industry standards. This strategic focus not only enhances research efficiency but also opens new avenues for therapeutic discovery. As a global supplier, we understand the diverse needs of our customers. Our comprehensive service model, backed by a wealth of scientific knowledge, allows us to provide tailored solutions that empower researchers and clinicians worldwide. Partner with Alpha Lifetech Inc. to access cutting-edge reagents and stay ahead in the rapidly evolving field of biomedical research.

Trending Claudin18.2 Recombinant Antibody in 2025 Service Backed by Expertise

Parameter	Description	Value	Unit
Production Yield	Amount of antibody produced in one batch	150	mg
Purity Level	Percentage of the antibody that is the desired form	95	%
Binding Affinity	Strength of binding to the target antigen	8.5	nM
Shelf Life	Time period the antibody remains stable when stored properly	24	months
Application	Potential uses in research and clinical applications	Immunoassays	-

Claudin18.2 Antibody Research Trends: 2020-2025

The trend of Claudin18.2 antibody research is experiencing a significant upward trajectory from 2020 to 2025, as evidenced by the increasing number of published research papers. Starting from 25 publications in 2020, the count has escalated to 150 projected publications in 2025. This growth reflects heightened interest and investment in the understanding and therapeutic application of Claudin18.2, a vital molecule in various cancers, particularly gastric cancer. The data illustrates a consistent year-over-year increase in the volume of research dedicated to this antibody, suggesting that not only is awareness of its potential rising, but also the scientific community's commitment to exploring its role in targeted therapies. This increase could be attributed to advancements in research methodologies, funding allocations toward oncological studies, and the growing body of evidence supporting the clinical relevance of Claudin18.2. As we move into 2025, this trajectory indicates an exciting period for both researchers and patients alike, heralding new developments in cancer treatment options that may integrate Claudin18.2 targeted therapies.